➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Express Scripts
McKesson
Merck
Medtronic

Last Updated: September 17, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,071,644


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,071,644 protect, and when does it expire?

Patent 8,071,644 protects EPIDUO and is included in one NDA.

This patent has thirty-five patent family members in twenty-two countries.

Summary for Patent: 8,071,644
Title:Combinations of adapalene and benzoyl peroxide for treating acne lesions
Abstract: Adapalene or a pharmaceutically acceptable salt thereof formulated into a pharmaceutical composition is useful for reducing the number of acne lesions, via daily topical application, in combination or in association with benzoyl peroxide (BPO); such treatment may be via administration of a pharmaceutical composition combining adapalene and BPO or by a concomitant application of two pharmaceutical compositions, one containing adapalene and the other containing BPO.
Inventor(s): Abou-Chacra Vernet; Marie-line (Nice, FR), Gross; Denis (Callian, FR), Loesche; Christian (Valbonne, FR), Poncet; Michel (Mougins, FR)
Assignee: Galderma Research & Development (Biot, FR)
Application Number:12/318,937
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,071,644
Patent Claim Types:
see list of patent claims
Use; Compound;

Drugs Protected by US Patent 8,071,644

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Galderma Labs Lp EPIDUO adapalene; benzoyl peroxide GEL;TOPICAL 022320-001 Dec 8, 2008 AB RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y TREATMENT OF ACNE ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,071,644

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France06 52968Jul 13, 2006

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Express Scripts
Harvard Business School
Moodys
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.